Publicação científica trimestral do CREMERJ

58 Pancreatite autoimune José Galvão-Alves, Bruna Cerbino de Souza Med. Ciên. e Arte , Rio de Janeiro, v.1, n.1, p.45-58, jan-mar 2022 28. Kwon JH, Kim JH, Kim SY, Byun JH, Kim HJ, Lee MG, Lee SS. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase. Eur Radiol. 2019 Nov;29(11):5763-5771. doi: 10.1007/s00330-019-06200-0. Epub 2019 Apr 26. PMID: 31028441 29. KimHJ, KimYK, JeongWK, LeeWJ, Choi D (2015) Pancreatic duct “icicle sign” onMRI for distinguishing autoimmune pan- creatitis from pancreatic ductal adenocarcinoma in the proximal pancreas. Eur Radiol 25 (6):1551-1560. 30. Vendrami CL, Shin JS, Hammond NA, Kothari K, Mittal PK, Miller FH. Differentiation of focal autoimmune pancreatitis from pancreatic ductal adenocarcinoma . Abdom Radiol (NY) 2020 May;45(5):1371-1386. 31. Fritscher-Ravens A, Brand L, Knofel WT, Bobrowski C, Topa-lidis T, Thonke F, de Werth A, Soehendra N (2002). Comparison of endoscopic ultrasound-guided fine needle aspiration for focal pancreatic lesions in patients with normal parenchyma and chronic pancreatitis. Am J Gastroenterol 97 (11):2768-2775. 32. Savides TJ, Donohue M, Hunt G, Al-Haddad M, Aslanian H, Ben- Menachem T, et al. (2007). EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurement. Gastrointestinal endoscopy 66 (2):277-282. 33. Lee TY, Kim MH, Park DH, Seo DW, Lee SK, Kim JS, Lee KT (2009). Utility of 18F-FDG PET/CT for differentiation of autoim- mune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol 193 (2):343-348. 34. Fujinaga Y, Kadoya M, Kawa S, Hamano H, Ueda K, Momose M, Kawakami S, Yamazaki S, Hatta T, Sugiyama Y (2010) Characteristic findings in images of extra-pancreatic lesions associated with autoimmune pancreatitis. Eur J Radiol 76 (2):228-238. 35. Manfredi R, Frulloni L, Mantovani W, Bonatti M, Graziani R, Pozzi Mucelli R (2011). Autoimmune pancreatitis: pancreatic and extrapancreatic MR imaging-MR cholangiopancreatography findings at diagnosis, after steroid therapy, and at recurrence. Radiol- ogy 260 (2):428-436. 36. Miller FH, Rini NJ, Keppke AL (2006). MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol 187 (4):W365-374. 37. CHARI ST, SMYRK TC. et al. Diagnosis of autoimmune pancreatitis: The Mayo Clinic experience. Clin. Gastroent. Hepatol., 4: 1010-6, 2006. 38. Shimosegawa T et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011 Apr;40(3):352-8. 39. Okazaki K, Chari ST, Frulloni L, Lerch MM, Kamisawa T, Kawa S, Kim MH, Lévy P, Masamune A, Webster G, Shimosegawa T. International consensus for the treatment of autoimmune pancreatitis. Pancreatology Jan-Feb 2017;17(1):1-6. 40. Shirakashi M, Yoshifuji H, Kodama Y, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep . 2018;8:10262. 41. Tacelli M, Celsa C, Magro B, Barresi L, Guastella S, Capurso G, et al. Risk factors for rate of relapse and effects of steroid maintenance therapy in patients with autoimmune pancreatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019;17(6):1061–72. 42. Takuma K, Kamisawa T, Tabata T, Inaba Y, Egawa N, Igarashi Y. Short-term and long-term outcomes of autoimmune pancreatitis. Eur J Gastroenterol Hepatol. 2011;23:146–152.